27 September 2021
The TTRA, a Medical Research Future Fund initiative delivered by MTPConnect, is supporting new research approaches to improve the prevention, diagnosis, treatment and management of diabetes, cardiovascular disease and their related complications.
The TTRA Research Projects provide funding of between $200,000 - $750,000 to help eligible organisations develop innovative preventative, diagnostic, therapeutic and/or disease management products/solutions for identified priorities associated with diabetes and cardiovascular disease.
TTRA Research Projects Round 2 Expressions of Interests must address one of the following Priority Areas:
- Priority 1: Atherosclerosis, including cerebrovascular disease
- Priority 2: Cardiomyopathy and heart failure
- Priority 3: Obesity as it relates to diabetes
- Priority 4: Mental health as it relates to diabetes
- Priority 5: Glucose control in type 1 diabetes (T1D), type 2 diabetes (T2D), double diabetes and/or gestational diabetes mellitus (GDM)
The project term for funded TTRA Research Projects is a maximum of 24 months. Applicants will be required to provide a co-contribution to the value of 50% of the TTRA funding request to be eligible. Additional in-kind or cash contributions above this threshold will be viewed favourably.
Further information about eligibility and the application process can be found in the detailed Funding Guidelines. All submissions must be made through SmartyGrants. The sample EOI application form provides an overview of what is required in your EOI.
Join our Zoom Information Session on Tuesday 12 October at to 11:00am AEDT to learn more – register now.
Round Two closes on Thursday 4 November 2021 at 4:00pm AEDT.
For queries, please contact the TTRA team via email on ttra‑firstname.lastname@example.org.